Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: an observational cohort
Xiangjun Guo1, Mengmeng Li1, Xin Wang1
1Department of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
Background:
SMAD4 has been found to be inactivated to varying degrees in many types of cancer; the purpose of this study was to investigate the correlation between SMAD4 expression in non-small cell lung cancer (NSCLC) and clinical pathological parameters.
Methods:
The serum concentration of SMAD4 was measured by enzyme-linked immunosorbent assay and its histological expression was quantified by immunohistochemistry.
Results:
The serum concentration of Smad4 in patients with NSCLC was lower than that in benign lung disease patients and healthy individuals (P < 0.001) and its concentration was related to the histological classification, pathological differentiation, lymphatic metastasis and clinical stage of NSCLC. The sensitivity and specificity of serum Smad4 were 91.56% and 61.56% for screening NSCLC from healthy individuals and 84.55% and 60.36% for screening NSCLC from patients with benign lung disease. Logistic regression analysis showed that the degree of cell differentiation (P < 0.001), lymph node metastasis (P < 0.001) and clinical stage of NSCLC (P = 0.007) affected the expression of Smad4, and had a strong correlation with the expression of Smad4. The expression of Smad4 in NSCLC tissues was lower than that in normal lung tissues (P = 0.009) and its expression was related to the degree of tissue differentiation, lymph node metastasis and clinical stage (P < 0.05).
Conclusions:
The downregulation or deletion of Smad4 is related to the malignant biological behavior of NSCLC and serum Smad4 could be considered as a potential molecular indicator for diagnosis and evaluation of NSCLC.
Insights
SMAD4 (Smad family member 4) is downregulated in non-small cell lung cancer (NSCLC). Lower serum and tissue SMAD4 levels correlate with advanced NSCLC, suggesting its potential as a diagnostic marker.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- SMAD4 is frequently inactivated in various cancers.
- Its role in non-small cell lung cancer (NSCLC) requires further investigation.
Purpose of the Study:
- To investigate the correlation between SMAD4 expression in NSCLC and clinical pathological parameters.
- To evaluate SMAD4 as a potential diagnostic and evaluative marker for NSCLC.
Main Methods:
- Serum SMAD4 concentration measured by enzyme-linked immunosorbent assay (ELISA).
- Histological SMAD4 expression quantified by immunohistochemistry.
- Statistical analysis including logistic regression.
Main Results:
- Serum SMAD4 levels were significantly lower in NSCLC patients compared to benign lung disease patients and healthy individuals.
- SMAD4 expression in NSCLC tissues was lower than in normal lung tissues.
- SMAD4 levels correlated with histological classification, differentiation, lymph node metastasis, and clinical stage.
Conclusions:
- Downregulation or deletion of SMAD4 is linked to malignant behavior in NSCLC.
- Serum SMAD4 shows potential as a molecular indicator for NSCLC diagnosis and evaluation.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
01:21Cancer Survival Analysis
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:25Statistical Methods for Analyzing Epidemiological Data